Coronary Artery Disease
Conditions
Keywords
Anti-platelet therapy
Brief summary
The purpose of this study is to evaluate safety of reduction of thienopyridine treatment period to 3 months after implantation of Cobalt-Chromium everolimus-eluting Stents.
Detailed description
Thienopyridine antiplatelet agents have markedly inhibited incidence of stent thrombosis, when they were combined with aspirin for 1 month after implantation of bare-metal stent (BMS). On the other hand, combination of aspirin with thienopyridine (dual antiplatelet therapy: DAPT) for more than 1 year after drug-eluting stent (DES) implantation is frequently used to prevent very late stent thrombosis in the current clinical practice. In the RESET study, which was carried out in clinical practice in Japan, DAPT was performed for at least 1 year in 90% of the patients. However, there has been no report showing that long-term thienopyridine treatment for at least 1 year reduces incidence of serious cardiovascular events, and large-scale observational studies or small-scale randomized comparative studies have demonstrated that thienopyridine treatment for 6 months or for at least 12 months does not reduce incidence of serious cardiovascular events. These results suggest that the optimal duration of DAPT after DES implantation may be shorter than 6 months. With respect to Everolimus-eluting stent (EES), which is the most widely used DES in Japan, it has been associated with significantly lower incidence of early or late stent thrombosis compared with the first-generation DES and with BMS in large-scale observational study and randomized comparative studies and their meta-analyses. Considering that long-term DAPT obviously increases hemorrhagic complications compared to Aspirin monotherapy, it is desirable to reduce the duration of DAPT as far as possible, if long-term DAPT is not effective in inhibiting the incidence of serious cardiovascular events. Moreover, long-term DAPT enormously increases medical expenses. In this study, we planned an exploratory multicenter study to evaluate incidences of cardiovascular events and bleeding events at 12 months after stent implantation using an EES (XIENCE Prime™), which is associated with low risk of stent thrombosis, when thienopyridine therapy is discontinued at 3 months after surgery.
Interventions
DRUGThienopyridine for 3 months
Sponsors
Takeshi Morimoto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who received PCI using everolimus-eluting cobalt-chromium stents
Exclusion criteria
* Patients who had been implanted drug-eluting stents other than everolimus-eluting cobalt-chromium stents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major cardiovascular and bleeding events | 1-year | Composite of cardiovascular death, myocardial infarction, stroke (ischemic and hemorrhagic), stent thrombosis (definite stent thrombosis not resulting in myocardial infarction), and major bleeding (TIMI Major/Minor) Cardiovascular death, myocardial infarction and stent thrombosis are defined according to the definition in the Academic Research Consortium (ARC). Stroke is defined as ischemic or hemorrhagic stroke with symptoms lasting \> 24 hour. Major bleeding is defined according to the definition in the Thrombosis in Myocardial Infarction (TIMI). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major bleeding (TIMI Major/Minor) | 1-year | Major bleeding (TIMI Major/Minor) |
| Death/MI | 1-year | Composite of all-cause death and myocardial infarction |
| All-cause death | 1-year | All-cause death |
| Cardiovascular death/MI | 1-year | Composite of cardiovascular death and myocardial infarction |
| Cardiovascular death | 1-year | Cardiovascular death |
| MI | 1-year | Myocardial infarction |
| Stroke | 1-year | Both ischemic and hemorrhagic stroke excluding transient ischemic attack |
| Stent Thrombosis | 1-year | Stent thrombosis according to Academic Research Consortium classification |
| Cardiovascular death/MI/stroke/definite ST | 1-year | Composite of cardiovascular death, myocardial infarction, stroke, and definite stent thrombosis |
| Target Vessel Failure | 1-year | Composite of cardiovascular death, myocardial infarction, and target vessel revascularization |
| Major Adverse Cardiac Events | 1-year | Composite of cardiovascular death, myocardial infarction, and clinically-driven target lesion revascularization |
| Target Lesion Revascularization | 1-year | Target lesion revascularization |
| Clinically-driven Target Lesion Revascularization | 1-year | Clinically-driven Target Lesion Revascularization |
| Non Target Lesion Revascularization | 1-year | Revascularization for non-target vessel or target vessel but target lesion |
| CABG | 1-year | Coronary artery bypass graft |
| Target Vessel Revascularization | 1-year | Target vessel revascularization |
| Any bleeding | 1-year | Any bleeding complications |
| Target Lesion Failure | 1-year | Composite of cardiovascular death, myocardial infarction due to target vessel, and target lesion revascularization |
Countries
Japan
Outcome results
None listed